Literature DB >> 16110326

Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin.

Leander Grode1, Peter Seiler, Sven Baumann, Jürgen Hess, Volker Brinkmann, Ali Nasser Eddine, Peggy Mann, Christian Goosmann, Silke Bandermann, Debbie Smith, Gregory J Bancroft, Jean-Marc Reyrat, Dick van Soolingen, Bärbel Raupach, Stefan H E Kaufmann.   

Abstract

The tuberculosis vaccine Mycobacterium bovis bacille Calmette-Guérin (BCG) was equipped with the membrane-perforating listeriolysin (Hly) of Listeria monocytogenes, which was shown to improve protection against Mycobacterium tuberculosis. Following aerosol challenge, the Hly-secreting recombinant BCG (hly+ rBCG) vaccine was shown to protect significantly better against aerosol infection with M. tuberculosis than did the parental BCG strain. The isogenic, urease C-deficient hly+ rBCG (DeltaureC hly+ rBCG) vaccine, providing an intraphagosomal pH closer to the acidic pH optimum for Hly activity, exhibited still higher vaccine efficacy than parental BCG. DeltaureC hly+ rBCG also induced profound protection against a member of the M. tuberculosis Beijing/W genotype family while parental BCG failed to do so consistently. Hly not only promoted antigen translocation into the cytoplasm but also apoptosis of infected macrophages. We concluded that superior vaccine efficacy of DeltaureC hly+ rBCG as compared with parental BCG is primarily based on improved cross-priming, which causes enhanced T cell-mediated immunity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16110326      PMCID: PMC1187936          DOI: 10.1172/JCI24617

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  42 in total

1.  Boosting vaccine for tuberculosis.

Authors:  J V Brooks; A A Frank; M A Keen; J T Bellisle; I M Orme
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

2.  Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model.

Authors:  M A Horwitz; G Harth; B J Dillon; S Maslesa-Galic'
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

3.  Virulent Mycobacterium tuberculosis strains evade apoptosis of infected alveolar macrophages.

Authors:  J Keane; H G Remold; H Kornfeld
Journal:  J Immunol       Date:  2000-02-15       Impact factor: 5.422

4.  Cytokine activation leads to acidification and increases maturation of Mycobacterium avium-containing phagosomes in murine macrophages.

Authors:  U E Schaible; S Sturgill-Koszycki; P H Schlesinger; D G Russell
Journal:  J Immunol       Date:  1998-02-01       Impact factor: 5.422

5.  Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans.

Authors:  Helen McShane; Ansar A Pathan; Clare R Sander; Sheila M Keating; Sarah C Gilbert; Kris Huygen; Helen A Fletcher; Adrian V S Hill
Journal:  Nat Med       Date:  2004-10-24       Impact factor: 53.440

6.  Apoptosis of mouse dendritic cells is triggered by listeriolysin, the major virulence determinant of Listeria monocytogenes.

Authors:  C A Guzmán; E Domann; M Rohde; D Bruder; A Darji; S Weiss; J Wehland; T Chakraborty; K N Timmis
Journal:  Mol Microbiol       Date:  1996-04       Impact factor: 3.501

7.  Apoptosis of macrophages and T cells in tuberculosis associated caseous necrosis.

Authors:  A Fayyazi; B Eichmeyer; A Soruri; S Schweyer; J Herms; P Schwarz; H J Radzun
Journal:  J Pathol       Date:  2000-08       Impact factor: 7.996

8.  Urease activity does not contribute dramatically to persistence of Mycobacterium bovis bacillus Calmette-Guérin.

Authors:  J M Reyrat; G Lopez-Ramirez; C Ofredo; B Gicquel; N Winter
Journal:  Infect Immun       Date:  1996-09       Impact factor: 3.441

Review 9.  Molecular epidemiology of tuberculosis and other mycobacterial infections: main methodologies and achievements.

Authors:  D Van Soolingen
Journal:  J Intern Med       Date:  2001-01       Impact factor: 8.989

Review 10.  Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis.

Authors:  Stefan H E Kaufmann; Andrew J McMichael
Journal:  Nat Med       Date:  2005-04       Impact factor: 53.440

View more
  192 in total

1.  Surface expression of MPT64 as a fusion with the PE domain of PE_PGRS33 enhances Mycobacterium bovis BCG protective activity against Mycobacterium tuberculosis in mice.

Authors:  Michela Sali; Gabriele Di Sante; Alessandro Cascioferro; Antonella Zumbo; Chiara Nicolò; Valentina Donà; Stefano Rocca; Annabella Procoli; Matteo Morandi; Francesco Ria; Giorgio Palù; Giovanni Fadda; Riccardo Manganelli; Giovanni Delogu
Journal:  Infect Immun       Date:  2010-10-04       Impact factor: 3.441

2.  Bacillus Calmette-Guérin vaccination using a microneedle patch.

Authors:  Yasuhiro Hiraishi; Subhadra Nandakumar; Seong-O Choi; Jeong Woo Lee; Yeu-Chun Kim; James E Posey; Suraj B Sable; Mark R Prausnitz
Journal:  Vaccine       Date:  2011-01-28       Impact factor: 3.641

3.  OX40 ligand fusion protein delivered simultaneously with the BCG vaccine provides superior protection against murine Mycobacterium tuberculosis infection.

Authors:  Robert J Snelgrove; Megan M Cornere; Lorna Edwards; Belinda Dagg; James Keeble; Angela Rodgers; Daphne E Lyonga; Graham R Stewart; Douglas B Young; Barry Walker; Tracy Hussell
Journal:  J Infect Dis       Date:  2012-02-07       Impact factor: 5.226

4.  Tuberculosis vaccine promises sterilizing immunity.

Authors:  Helen McShane; Ann Williams
Journal:  Nat Med       Date:  2011-10-11       Impact factor: 53.440

5.  Urease activity represents an alternative pathway for Mycobacterium tuberculosis nitrogen metabolism.

Authors:  Wenwei Lin; Vanessa Mathys; Emily Lei Yin Ang; Vanessa Hui Qi Koh; Julia María Martínez Gómez; Michelle Lay Teng Ang; Siti Zarina Zainul Rahim; Mai Ping Tan; Kevin Pethe; Sylvie Alonso
Journal:  Infect Immun       Date:  2012-05-29       Impact factor: 3.441

6.  Protective efficacy of a recombinant BCG secreting antigen 85B/Rv3425 fusion protein against Mycobacterium tuberculosis infection in mice.

Authors:  Jiuling Wang; Yaqing Qie; Wei Liu; Honghai Wang
Journal:  Hum Vaccin Immunother       Date:  2012-08-21       Impact factor: 3.452

7.  Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.

Authors:  Mark Hatherill; Hendrik Geldenhuys; Bernadette Pienaar; Sara Suliman; Phalkun Chheng; Sara M Debanne; Daniel F Hoft; W Henry Boom; Willem A Hanekom; John L Johnson
Journal:  Vaccine       Date:  2014-05-09       Impact factor: 3.641

Review 8.  CD8 T cells and Mycobacterium tuberculosis infection.

Authors:  Philana Ling Lin; JoAnne L Flynn
Journal:  Semin Immunopathol       Date:  2015-04-28       Impact factor: 9.623

9.  The same well-characterized T cell epitope SIINFEKL expressed in the context of a cytoplasmic or secreted protein in BCG induces different CD8+ T cell responses.

Authors:  Paul D Hulseberg; Alla Zozulya; Hamlet H Chu; James A Triccas; Zsuzsanna Fabry; Matyas Sandor
Journal:  Immunol Lett       Date:  2009-12-11       Impact factor: 3.685

10.  The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis.

Authors:  Claire Swetman Andersen; Jes Dietrich; Else Marie Agger; Nils Y Lycke; Karin Lövgren; Peter Andersen
Journal:  Infect Immun       Date:  2006-10-30       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.